A smart P-gp inhibitor-drug conjugate nanomedicine overcomes administration challenges and multidrug resistance in breast cancer therapy

Key Points

• This research aims to enhance the efficacy of docetaxel in breast cancer treatment by overcoming multidrug resistance.
• Developed a P-glycoprotein inhibitor-drug conjugate nanomedicine
• Tested the efficacy of the conjugate in preclinical models of breast cancer
• Evaluated the impact on drug delivery and resistance mechanisms
• The nanomedicine significantly improved the effectiveness of docetaxel against resistant breast cancer cells
• Demonstrated reduced instances of drug resistance compared to standard treatments
• Enhanced drug accumulation in target tissues was observed